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1. Introduction 
InforMatrix is an interactive matrix model, in which pharmacotherapeutic strategies are 
supported in a rational manner by means of a transparent selection methodology. This is 
achieved through the use of an independent reporting made by interactive workshops in the 
field, in which participants are facilitated in the determination of their own preference.  
The treatment of AIDS is directed by guidelines and continually being modified as a result 
of ongoing research and the arrival of new treatment options. The goal of this InforMatrix 
program on backbones of nucleoside/nucleotide reverse transcriptase inhibitors is to make 
a rational selection of a first choice medication possible. It is important in this to describe the 
selection process and to make this process transparent. The InforMatrix methodology is a 
tool in this, in which selection criteria are described; tested against the available literature 
and the various therapeutic alternatives evaluated as to their clinical value.  
Below follows a short description of the InforMatrix methodology, of the subject, and a 
description of the various selection criteria. 
1.1 InforMatrix methodology 
InforMatrix is a so-called decision matrix technique, with which a group of experts in the 
subject determine, on the basis of criteria, an order of merit within various treatment options 
which have similar objectives. In this order of merit, the criteria are weighed against each 
other. After all, they do not all carry the same weight. Next, the various options per criterion 
are compared to each other. Data is necessary for this, both from literature as well as from 
own practice experience. The literature is tested by an independent ethisor for clinical value 
and evaluated per criterion. 
The InforMatrix technique has six set criteria. These criteria are: 
- Effectiveness (the actualization of positive outcomes and treatment goas) 
- Safety (the avoidance of negative outcomes, such as hazardous side effects) 
- Tolerance (the interruption of the care process due to less hazardous, generally  
transitory, but disturbing side effects) 
- Users’ ease (ease for the patient, for example, dosing frequency) 
- Usability (what is the scope of the treatment freedom (interactions and such) and the 
ease for the caregiver) 
- Costs (price per month) 
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These criteria are specifically described per selection subject (“operationalized”).  
The InforMatrix technique takes place in the following steps: 
 Operationalization of the six criteria 
 Literature synthesis 
 Relative weighing of the six criteria 
 Evaluation of the various treatment options on the basis of the literature and own 
knowledge and experience 
 Synthesis of the weightings and evaluations in the selection matrix: calculation of order 
of merit 
A group of experts in the field are requested to test the operationalization of the above six 
selection criteria in the framework of the treatment of HIV/AIDS in the care process for 
relevance. Following on to these selection aspects, the authors execute a literature synthesis. 
This results in a report, in which these means are evaluated on the basis of these selection 
criteria by a group of experts in the field. In this, the report is tested as far as its applicability 
in making a rational consideration of the treatment options  possible. 
The choice of nucleoside/nuclotide reverse transcriptase inhibitors and the assessment 
criteria 
After the introduction of nucleoside/nuclotide reverse transcriptase inhibitors (NRTIs), the 
first antiretroviral drugs approved for the treatment of HIV, patients were initially treated 
with one drug (monotherapy) and later with two NRTIs (duotherapy). After the 
introduction of protease inhibitors effective treatment of the HIV infection was possible. 
This so called HAART (highly active antiretroviral therapy) initially consisted of a 
combination of 2NRTIs with a proteaseinhibitor (PI).  
New classes of antiretrovirals have been developed and nowadays many more 
combinations of antiretrovirals are possible. A backbone therapy consisting of 2NRTIs in 
combination with a third drugs like a PI, a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) or an integrase inhibitor is still chosen as an initial combination antiretroviral 
therapy (cART). 
The treatment goal of cART is to attain an undetectable plasma viral HIV-1 load (VL), after 
which a recovery of immunity usually follows.  
In a meta-analysis covering 64 clinical trials with in total 10,559 naive patients HAART 
consisting of 2NRTI/PI/ritonavir or 2NRTI/NNRTI both produce significantly higher 
percentages of patients with undetectable VL and a significantly higher increase of CD4 
positive T-lymphocytescount (CD4 cell count) than cART consisting of  2NRTI/PI or 
3NRTI (1).  
Although stavudine (d4T) is a effective anti-retroviral drug, especially in combination with 
didanosine, its use is no longer recommended because of the increased change for the 
development of lipoatrophy during treatment and high rates of mitochondrial toxicity (2).   
Combining ddI with tenofovir leads to a specific renal interaction causing high drug levels 
of didanosine and ddI toxicity  resulting in decrease of CD4 cell count (3). Lowering of ddI 
dosing leads to an increased change of developing virological failure (4). 
The following combinations are compared in this InforMatrix because they are 
recommended in the three major guidelines, the American DHHS Panel (December, 2009) 
(5), the European AIDS Clinical Society (November, 2009) (6) and the International AIDS 
Society-USA Panel (7) 
a.  Abacavir/lamivudine (fixed dose combination Kivexa® or Epzicom®) abbreviated 
as ABC/3TC 
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b.  Didanosine/lamivudine or emtricitabine abbreviated as ddI/3TC or FTC 
c.  Tenofovir/emtricitabine (fixed dose combination Truvada®) abbreviated as 
TDF/FTC 
d.  Zidovudine/eamivudine (fixed dose combination Combivir®) abbreviated as 
ZVD/3TC 
The following criteria and subcriteria were used: 
1. Efficacy of anti-retroviral backbones  
1.1 Parameters of efficacy of anti-retroviral backbones 
1.2 Compliance, quality of life and durability of anti-retroviral backbones 
1.3 Development of resistance during treatment with anti-retroviral backbones  
2. Safety of anti-retroviral backbones  
1.4 Grade 3 and 4, serious adverse events  
1.5 Documentation 
3. Tolerability of anti-retroviral backbones 
1.6 Grade 1 and 2, mild to moderate adverse events  
4. Easy of use 
1.7 Dosage frequency, number of tablets per day 
5. Applicability 
1.8 Available strengths 
1.9 Drug interactions 
1.10 Approved indications 
1.11 Contra-indications 
1.12 Use in children and elderly 
1.13 Use in renal and hepatic disease 
1.14 Use in pregancy and lactation 
1.15 Special precautions 
6. Cost 
2. Efficacy of anti-retroviral backbones  
2.1 Parameters of efficacy of anti-retroviral backbones 
The efficacy of a cART, usually consisting of 2NRTIs in combination with a  PI or  NNRTI is 
judged by the results of its anti-retroviral efficacy, increase of CD4 cell count and change of 
developing resistance.  
The combination of 3 NRTIs as initial therapy is no longer used since the availability of the 
results of the ACTG 5095 study (8). Limited data are available on combinations of one NRTI 
+ NNRTI+PI the so called NUC-sparing regimen or other combinations. In has been shown 
in meta-analyses that HAART consisting of 2NRTIs + PI, not combined with ritonavir (as a 
booster) is virologically and immunologically less effective than 2NRTIs+NNRTI or 2NRTIs 
+ PI  combined with ritonavir (1). 
The anti-retroviral efficacy of cART must lead to undetectable VL, less than 50 copies/mL 
(VL<50 c/mL), in older studies a pVL < 400 c/mL is used as measure of undetectability.  
If the VL does not become undetectable this almost always leads to the development of 
resistance and to antiviral inefficacy of a certain drug or a whole class of drugs resulting in a 
decrease of  the CD4 cells. This ongoing decrease in the number of CD4 cells leads to HIV 
related diseases, AIDS and death. The antiviral efficacy is one of the most important 
parameter for the efficacy of a certain regimen. Te so called “regimen failure” which is a 
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broader measure effectivity of an antiretroviral regimen includes not only virological failure 
but all other reaons for stopping a regimen such as adverse effects or death and indicates its 
clinical efficacy.   
Studies in patients who are not pretreated (naive patients) and harbouring no significant 
resistant mutations provide the best indication of the antiviral and clinical efficacy.  
The percentage of naive patients in a certain study after 48 weeks, but preferably longer, in 
the intent to treat analysis (ITT) showing a VL<50 c/mL, is regarded as the best parameter 
for clinical efficacy. Often missing data on participants (M) are considered as virologic 
failures (F) (ITT analysis M=F) (5).  
Increase of CD4 cell count is of less importance as a parameter of efficacy, because an 
undetectable VL almost always leads to recovery of CD4 cell count and the mean increase in 
CD4 cell count is probably similar in the different strata of  CD4 cell count when starting 
cART. For instance in the Athena Dutch cohort study  the average increase in CD4 cell count 
after initiation of therapy was around 70 cells/mm3 per year during seven years of 
continuous cART with an undetectable VL. In the first six months after start of cART the 
increase was on average around 140 cells/mm3 . Patients  starting cART when the CD4 cell 
count was above 500 cells/mm3 had on average a lower increase CD4 cell of around  40 
cells/mm3 per year (9). 
There are seven major randomized studies (10-17) comparing backbones combined with a 
similar third drug. The results of these comparative studies are summarised in Table 1. 
In the three above mentioned guidelines two (3,5) recommend  to start with  TDF/FTC and 
ABC/3TC as an alternative to start with.  
-In the HEAT (10) and  ACTG 5202 (11,12) these two fixed dose combinations were 
compared with each other. In the HEAT study the third drug was a PI, lopinavir/ritonavir 
and in the ACTG 5202 it was a NNRTI, efavirenz or a PI, atazanavir/ritonavir.  The HEAT 
study is an industry sponsered study.  
ABC is known for its hypersensitivity reaction usually appearing in the first six week after 
starting ABC therapy. This hypersensitivity can lead to serious complications and death if 
not recognized. The presence of  HLA-B5701 antigen  is highly predictive for the chance of 
developing this hypersensitivity reaction (18).  
In boths studies no determination for the presence of  HLA-B5701 antigen was done.    
In the HEAT study (10) the effectivity and CD4 cell count increase of both regimens after 48 
weeks of treatment and safety after  96 weeks of treatmet was similar. In both treatment 
arms 2%  of the participants had a grade 3-4  (19) decrease in renal function.  
Of importance in this study is the fact that there was no difference in anti-vial efficacy 
between both treatment arms for participants with a high screening VL greater than 
100,000 copies/ml (high VL). In the ACTG 5202 the anti-viral efficacy of the regimens 
were similar for participants with a screening VL less than 100,000 copies/ml (12) but not 
for those participants with a high screening VL. In the ACTG 5202, 43% of the participants 
had a  high screening VL (11). At a median follow-up of 60 weeks, among the 797 patients 
with high VL, the time to virologic failure was significantly shorter in the ABC/3TC 
group than in the TDF/FTC group. There were 57 virologic failures (14%) in the 
ABC/3TC group versus 26 (7%) in the TDF/FTC group. The time to the first adverse 
event was also significantly shorter in the ABC/3TC arm. The increase in CD4 cells from 
baseline at week 48 was similar.  
In an analysis of  five pharmaceutical company sponsored trials with 872 paticipants with 
high sreening VL treated with  ABC/3TC and using the same criteria for virological 
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failure as in the ACTG 5202 study  there was no inceased chance for virological failure in 
this group (20).  
But in a meta-analysis of  12 trials with  4896 participants and also using the same criteria for 
virological failure as in the ACTG 5202 study  TDF/FTC showed to be virological more 
effective than ABC/3TC (21).  
-In a number of trials (13-17) (see table 1) combination regimens with  ZVD or combination 
regimens with d4T are less effective or result in a lower increase of CD4 cell count than in 
the comparative study arm.  
For instance in two trials comparing  ABC/3TC with  ZVD/3TC (14) and  TDF/FTC with 
ZVD/3TC (13) a significant lower increase in CD4 count is seen in both ZVD/3TC study 
arms than in the comparative study arms. In the 934 study (13) significant differences were 
seen in the proportion of patients with VL less than 50 copies/ml (80% versus 70%).  
Significant more patients in de ZVD/3TC arm had virologic failure, 4% versus <1% in the 
TDF arm.  
More patients in theZVD/3TC group than in the TDF/FTC group had adverse events 
resulting in discontinuation of the study drugs (13). These adverse events were mainly 
anemia, nausea, vomiting and fatigue. The authors concluded that through week 48, 
TDF/FTC proved to be superior in terms of virologic suppression, CD4 response and 
adverse events resulting in discontinuation of the study drugs. 
Also in other studies, serious adverse events like anemia and leukopenia are seen in patients 
taking  ZVD and are often a reason for stopping ZVD (14, 15).  
2.2 Compliance, quality of life and durability of anti-retroviral backbones 
Good compliance is the cornerstone for succes of anti-retroviral therapy. Stress reduction, a 
good sociaal network and adequate information play an important role (22). Irregular intake of 
medication by inadequate compliance leads to suboptimal plasma levels of the medication, 
thereby increasing development of resistance (23, 24) Compliance which leads to actual intake 
of > 95% of the prescribed medication is a predictor of efficacy of a regimen (23,24). 
Adverse events, the number of pills and dosage frequency determine compliance.   
In different meta-analyses of 64 (25) and 20 (26) clinical trials it was shown that the number of 
tablets per day, dosage fequency and diet restrictions (with food or on an empty stomach) are 
important determinants of success of antiretroviral therapy. In the meta-analysis of 64 clinical 
trials (25) the number of tablets per day was the most important factor for success of cART.  
A meta-analysis of 11 randomized trials revealed that the adherence rate was better with 
once-daily regimens than twice-daily regimens and this effect was more pronounced at the 
time of treatment initiation (27).  
No studies on quality of life (QoL) and compliance have been done linked to the seven 
major randomized studies mentioned above.  
In a meta analysis, initial ART regimens, regimens containing TDF are equivalent to those 
containing AZT concerning serious adverse events. However, TDF showed to be superior to 
AZT in terms of immunologic response and adherence and less frequent emergence of 
resistance (28).  
In a review of twenty-two randomized controlled trials including all above mentioned 
backbones, including 8,184 HIV-treatment-naïve patients, the combination ddI/3TC was 
anti-virologic more effective and less toxic for discontinuation due to adverse events and 
more tolerable than its comparators. The combination TDF/3TC or FTC was more effective 
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and less toxic only in the 144-week follow-up data (two trials, 1,119 patients). ABC/3TC had 
similar efficacy to its comparators, but more AIDS-defining events (29).  In the Swiss cohort 
study, including 1318 naïve patients, between 2005 and 2008 drug toxicity remained a 
frequent reason for treatment modification. Initial treatment with ZVD/3TC was associated 
with a high rate of drug toxicity. (30) In general QoL is beter with a higher CD4 cell count 
and QoL is decreased in patients with a high VL. The effects of adverse events on QoL are 
independent of CD4 cell count and VL (31).  
 
Acronime of 
study 
Set up of 
study 
Treatment arms
Number of 
patients in each 
treatment arm ()
Third drug ITT analysis:  
% patients 
with 
VL< 50 
cop/mL 
% patients 
with screening 
VL 
>100.000 
copies/mL 
 with VL< 50 
copies/mL 
CD4 
increase  
cells/mm3 
 % patients 
stopping study 
drugs due to 
adverse events 
HEAT Sudy 
#(10)   
randomised 
dubble blind
placebo 
controlled 
ABC/3TC (343)
versus  
TDF/FTC (345) 
lopinavir/r 68% vs 67% 63% vs 65% 214 vs 193 up to week 96: 
6% vs 6% 
ACTG 
5202# 
(11,12) 
randomised 
blinded for 
backbone 
ABC/3TC (388)
versus  
TDF/FTC (393) 
atazanavir/r 
or efavirenz 
similar 75% vs 80% 194 vs 199 up to week 112: 
5% vs 4% 
 
Gilead 934 
Study (13) 
randomised 
open label 
TDF/FTC(258) 
versus 
ZVD/3TC (259)
efavirenz 77% vs 68%** not available 190 vs 
158* 
up to week 48: 
5% vs 19%* 
up to week 144: 
13% vs 34%* 
 
CNA30024# 
(14) 
randomised 
dubble blind
ABC/3TC (327)
versus 
ZVD/3TC (327)
efavirenz 70% vs 69% 67% vs 67% 209 vs 
155** 
up to week 48: 
14% vs 18% 
GESIDA 
(15) 
randomised 
open label 
ddI/3TC (189)  
versus 
ZVD/3TC (187)
efavirenz 67% vs 63% 67% vs 63% 158 vs 163 up to week 48: 
14% vs 26% 
 
FTC 301 (16) randomised 
dubble blind
ddI/FTC (286)  
versus 
d4T/ddI (285)   
efavirenz 78% vs 59%*** 67% vs 50%*** 168 vs 134 up to week 60: 
7% vs 15% 
Gilead 903 
Study(17) 
randomised 
dubble blind
placebo 
controlled 
TDF/FTC (299)  
versus 
d4T/3TC (303)  
efavirenz  82% vs 81% not available 169 vs 167 up to week 48: 
9% vs 9% 
up to week 96: 
14% vs 15% 
Table 1. Major characteristics and parameters of effectiviness of the seven important clinical 
trials comparing different backbones of during 48 to 96 weeks of treatment 
# HLA-B57 screening test not done at inclusion 
Degree of significance between treatment arms * p< 0,05  ** p<0,005 ***p<0.001 
2.3 Resistance development during treatment with anti-retroviral backbones 
Inadequate compliance is the most important cause of virologic failure and resistance 
development (23,24). Repeated virologic failure with cumulation of resistances will lead to a 
decrease of the number of CD4 cells (immunologic failure), leading to HIV-related diseases, 
AIDS and death (clinical failure). 
Development of resistance varies per class of anti-retroviral drugs and also within a class of 
antiretrovirals. For NRTIs, the development of resistance after initiation of cART is stongly 
associated with adherence. Resistance to antiretrovirals from the start of cART will develop 
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first and during follow-up in highest frequency to lamivudine, followed by development of 
resistance to NNRTIs, NRTIs and PIs (32).  
A distinction between the different mutations to NRTI’s is made between thymidine analoge 
mutations (TAMs), TAMs-associated mutations, evolving mainly during virologic failure 
when on therapy with thymidine analogues ZVD and d4T and the discriminatory mutations 
and the Q151M pathway mutations conferring for multiresistance. Mutations, an 
acumulation of mutations or the occurrence of multi-resistant mutations limit the number of 
effective combinations of NRTIs in the backbone for a second or third  regimen.  
For instance the K65R mutation (discriminatory mutation) can develop during failing 
therapy with TDF and will make ABC and ddI ineffective. 
These drug-resistant viruses can be tranmitted and may limit the treatment options in 
treatment naïve patients.  
The prevalence of transmitted drug resistance viruses since 2004 is similar in different 
Eropean countries and the Netherlands. In the Netherlands the prevalence of NRTI drug 
resistance in recent infection (naïve patients) is found to be around 5-6% and for 
intermediate or high level of resistance is around 2% (33) 
Since2003 treatment guidelines recommend onbtaining a genotypic sequence at the start 
of cART. 
3. Safety of anti-retroviral backbones 
3.1 Grade 3 and 4, serious adverse events 
The prevalence and incidence of grade 3 (severe adverse event) and grade 4 (potentially life 
threatening adverse event) adverse events (table according to NIAID, Division of AIDS) (19)  
provide information on the safety of anti-retrovirals. It is not always possible to determine 
which adverse events are caused by an  individual drug or by the combination of drugs in a 
regimen.  Grade 3-4 adverse events have major  consequences for  the patient and may lead 
to significant morbidity, hospitalisation and mortality. The medication must almost always 
be stopped, leading to an increased risk of resistant mutations, decrease in CD4 cell count 
and resulting impairment of physical condition and a lower quality of life (22,23,24,31). 
Adverse events in the studies with mainly naive patients show highly variable incidences of 
grade 3 and 4 adverse events, ranging from 0-57%. On the basis of these studies, it is not 
possible to determine a certain pattern of side-effects. It is not clear which side-effects can be 
linked to the individual NRTI, to the backbone or other drugs. In some studies all grade 2-4 
side-effects are summarised without full details (10,14,16). In other studies report only a 
selection of grade 3 and 4 clinical and or only laboratory adverse events are reported (11,12).  
The percentage of patients stopping study drugs because of adverse events ranged up 
to 34% (see table1). Several adverse events with changing severity have been associated 
with NRTIs (34). 
Anemia, neutropenia and  thrombocytopenia  
Anemia and neutropenia (granulocytopenia) occur are 1.1-9.7% of the patients treated with 
ZVD. Higher percentages is seen in patients with AIDS, 15-61% (35). Serious grade 3 of 4 
anemia and neutropenia are relatively rare with earlier initiation of treatment. Hematologic 
toxicity is more often seen with ZVD and rarely to never in treatment with other NRTIs. 
Combinations of NRTIs with other hemato-toxic medication may increase the incidence of 
serious anemia and neutropenia (35). Serious grade 3 of 4 thrombocytopenia due to cART, 
necessitating thrombocytes transfusions have been reported (35).  
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Pancreatitis:  
In the older studies pancreatitis was seen in 4-7% of patients treated with ddI and d4T. In 
6% of these patients pancreatis was fatal (35). Combinations of ddI/d4T double the risk and 
ddI/TDF also increase the risk of development of pancreatitis (36).  
In the ACTG studies from October 1989 through July 1999 the overall pancreatitis rates were 
0.61 per 100 person-years clinical and 2.23 per 100 person-years clinical/laboratory (36). The 
incidence of pancreatitis in the EuroSida cohort decreased over the years with earlier start of 
therapy and with higher CD4 cell counts. The incidence was  0.127 per 100 person-years 
over the years 2001-2006 (38).  
Lactate acidosis (mitochondrial toxicity):  
Lactate acidosis is a serious complication of the treatment with NRTIs, which occurs in 
around 0.9 times per 1000 years of treatment and often leads to serious morbidity and 
mortality (35).  
In vitro studies have shown that inhibition of DNA polymerase gamma and other 
mitochondrial enzymes by NRTIs may lead to mitochondrial disfunction and cellular 
toxicity.  
The clinical symptomatology of NRTI-induced mitochondrial toxicity consists of steatosis, 
hepatitis, lactate acidosis, myopathy, nephrotoxicity, peripheral neuropathy and 
pancreatitis. Studies with NRTIs in enzym assays and in cell cultures have shown that the 
following NRTIs are responsible for  this mitochondrial toxicity, to a decreasing extent: ddI 
> d4T > ZVD (39). DNA polymerase gamma inhibition is not found in normal 
concentrations of ABC, 3TC and TDF (39). 
Lipodystrophy:  
Three forms of lipodystrophy are distinguished:  lipoatrophy caused by loss of 
subcutaneous fat,  fat accumulation or lipohypertrophy  and mixed forms. It was described 
with cART in 1997 and may occur in all combinations of cART medication with a  
prevalence between 2-84%. Lipo-accumumulation like buffelo-hump and “crix belli” may be 
caused by PIs, lipoatrophy by NRTIs. Lipoatrophy may occur shortly after initiation of 
cART. In a large observational cohort, 62% of the patients who developed lipoatrophy has 
symptoms within one year. In this cohort  a highly significant correlation was found 
between lipoatrophy and the use of d4T (40).  It has been shown  in observational cohort 
studies, clinical trials and in pathologic studies that lipoatrophy is specifically related to the 
use of NRTI especially d4T and in to a lesser extent to ZVD. Host factors have a modulating 
effect on the risk and the severity of lipoatrophy (2).  
The development of lipoatrophy is a serious complication which often leads to a marked 
decrease of the quality of life.  In clinical studies is was shown that  lipoatrophy improved 
by the replacement of ZVD or d4T  by ABC (41) or TDF (42).  
Peripheral neuropathy 
The occurrence of peripheral neuropathy is a well known complication of HIV-infection 
itself or due to a toxic effect on mitochondria induced by some NRTIs. Its incidence 
increases with the extent of immunodeficiency and older age. Patients who develop 
peripheral neuropathy tend to do so shortly after exposure to antiretroviral therapy and 
certain subgroup of patients are found to be more susceptible than others (43).   
With ddI use the incidence of medication related sensoric neuropathy was 6.8 cases per 100 
person years. In one study the relatieve risk is 1.4 fold higher in d4T use and 3.5 times 
higher in the combination of ddI/d4T compared to other NRTIs (44).  In an other study 
peripheral neuropathy was reported  in 3.0 cases per 100 person-years for ZVD 
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monotherapy  and  in 2.2 cases per 100 person-years for ZVD/ddl (43). Sensoric neuropathy 
has not been associated with the use of ABC,3TC, FTC and TDF. 
Rash (hypersensitivity reaction) and muscle disorders 
Drug hypersensitivity reactions are an important cause of morbidity in HIV-infected 
patients. The hypersensitivity reactions can be caused by each of the antiretroviral drugs in 
the cART regimen or by other concomitend prescribed drugs.  
ABC is known for its hypersensitivity reaction usually appearing in the first six week after 
starting ABC therapy. Symptoms of this ABC related hypersensitivity reaction are 
nonspecific and can be difficult to distinguish from reactions to other drugs or conditions 
and  can lead to serious complications and death if not recognized. The presence of  HLA-
B5701 antigen is highly predictive for the chance of developing this hypersensitivity 
reaction. ABC hypersensitivity reaction affects 5-8% of patients during the first six weeks of 
treatment (18).  
Hypersensitivity reactions to 3TC, FTC, ddI, TDF have been reported but occur very rarely 
(45). Other forms of  hypersensitivity reactions and rashes are related to the use of NNRTIs 
and PIs and are usually mild and self-limiting (46).   
Other serious adverse events like rhabdomyolysis, myopathy and cardiomyopathy are very 
rare complications, which are not clearly related to NRTIs. (46).  
Renal failure  
Chronic kidney disease in HIV-positive persons can be caused by both HIV and traditional 
or non-HIV-related factors and antiretroviral drugs. Tenofovir has been associated with 
decline in renal funtion (47,48,49). 
Tenofovir is mainly cleared by glomerular filtration and active tubular secretion through 
tubular transport proteins. Interactions and competition of different anti-retrovirals with 
these transport proteins can lead to renal toxicity and increased blood levels. The 
combination of TDF/ddI leads to ~ 30%  increased ddI levels and ddI related toxicity.  
Up to February 2006, 27 individual cases of  renal failure with or without proteinuria or 
Fanconi syndrome (renal tubular acidosis) have been described with the use of TDF (47). 
During a follow-up of 144 weeks of 600 patients in the 903 Study (17,50) comparing 
d4T/3TC/EFV with TDF/3TC/EFV no significant increases in mean creatinine level were 
seen in the 299 patients treated with tenofovir. In the Heat study (10) comparing ABC/3TC 
and TDF/FTC and in Study 934 (13) comparing ZVD/3TC and TDF/FTC during an 
obserervation period of respectively 96 weeks and 48 weeks no significant difference in 
renal function could be shown.  
In the Swiss HIV Cohort Study (48) 363 treatment-naive patients or patients with treatment 
interruptions of more than 12 months starting either a TDF-based cART  and 715 patients on 
a TDF-sparing regime were compared for the time to reach a 10 ml/min reduction in 
calculated GFR (cGFR). Apart from diabetes mellitus, higher baseline cGFR (by 10 ml/min), 
TDF use and boosted PI use were significantly associated with an increased risk for reaching 
a 10 ml/min reduction in cGFR during an observation time of two years.  
During a median follow-up of 3.7 years in the EuroSida Study Group (49) 225 (3.3%) persons 
progressed to chronic kidney disease during 21.482 person-years follow-up, an incidence of 
1.05 per 100 person-years follow-up. After adjustment for traditional factors associated with 
chronic kidney disease, increasing cumulative exposure to TDF and the PIs, indinavir, 
atazanavir and lopinavir/ritonavir were associated with a significantly increased rate of 
decline in renal function. No other antiretroviral drugs were associated with increased 
incidence of chronic kidney disease. 
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In a prospective observational cohort study at Johns Hopkins (51) patients taking both TDF 
and NRTIs experienced an initial decline in cGFR during the first 180 days of therapy, but 
cGFR stabilized between 180 and 720 days. In this study there was no difference between 
TDF and NRTI use in more than 25% or 50% decline in cGFR at 1 or 2 years or in change in 
cGFR at 6, 12, or 24 months. Those taking TDF and a PI/ritonavir had a greater median 
decline in cGFR than those taking TDF and a NNRTI at 6 months. There was no difference 
in median cGFR decline between those on an NRTI/PI/ritonavir versus those on an 
NRTI/NNRTI regimen. 
The reversibility of TDF-related nephrotoxicity in 24 male patients who ceased TDF for renal 
impairment by retrospective assessment were determined (52). Median eGFR pre-TDF was 
74 mL/min/1.73 m2 (using the Modified Diet in Renal Disease equation) and fell to 51 
mL/min/1.73 m2 at TDF cessation and increased to 58 mL/min/1.73 m2 in a median of 13 
months after TDF cessation. This decline in cGFR, most recent versus pre-TDF is significant. 
Results were similar using the Cockcroft-Gault equation for cGFR. Only 10 patients reached 
their pre-TDF cGFR.  
Many patients on antiretroviral therapy have multiple medical problems and may take other 
potentially nephrotoxic drugs. It has been clearly shown that taking TDF in combination 
with PI may increase a decline in renal function.   
In a systematic review (53) of  a total of 17 studies (including 9 randomized, controlled 
trials) a significantly greater loss of kidney function was seen among patients using TDF, 
compared with control subjects (mean difference in eGFR was 3.92 mL/min, as well as a 
greater risk of acute renal failure. There was no evidence that TDF use led to increased risk 
of severe proteinuria, hypophosphatemia, or fractures. 
Thus in some well designed randomized prospective trials (10,17,50)  no decline in renal 
function during treatment with TDF has been noted. Some observational stusies have found 
evidence of mild decrease in kidney function in TDF treated patients and when TDF related 
renal toxicity was present it was not always fully reversible.  
Cardiovascular risk and lipids 
The risk of cardio vascular disease (CVD) and other non-AIDS conditions increases with 
age, but prevalence of these diseases by age is greater in HIV-positive populations. In a case-
control study of HIV-infected patients and healthy HIV-negative individuals from an 
observational database comparing rates of 6 comorbidities,CVD, hypertension, renal failure, 
osteoporosis, diabetes, and hypothyroidism to be higher in HIV-infected patients (54). 
Numerous large observational cohort studies in Europe and the USA have found higher 
rates of acute myocardial infarction (MI) or coronary heart disease (CHD) in patients with 
HIV. (5-10) In a cross-sectional study of HIV-infected participants and controls without pre-
existing CVD preclinical atherosclerosis assessed by carotid intima-medial thickness 
measurements in the internal/bulb and common carotid regions in HIV-infected 
participants and controls after adjusting for traditional CVD risk factors showed that HIV 
infection was accompanied by more extensive atherosclerosis (61). 
The higher risk among patients with HIV-infected patients held true for every age group 
analyzed and in multivariate analysis adjusting for demographics and common 
cardiovascular risk factors confirm that HIV infection is an independent predictor of acute 
MI, conferring nearly a two-fold risk. The risk of myocardial infarcion is found to be 
associated with the cumulative use of PIs in these studies (55,56,59,60). 
In the D.A.D cohort, a lage observational prospective cohort study with more than 30,000 
HIV-infected patients in 212 clinics since 1999, it was found that ABC and ddI were 
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associated with a higher risk of acute MI within each CVD risk category defined by the 
Framingham Risk Score (62). Exposure to ABC within the most recent 6 months was 
associated with a 1.90 relative risk of acute MI. Subsequent analysis suggested cumulative 
use of ABC may also been associated with increased MI risk, although to a lesser extent than 
recent use (63).  Since that first publication, several reports on MI risk associated with ABC 
have appeared, and some of these analyses have not implicated ABC as an MI risk factor. 
Several studies have focused on possible mechanisms that may explain the increased risk on 
MI in patients taking ABC. In the largest analysis, SMART study investigators found higher 
levels of hsCRP and IL-6 in patients taking ABC than in patients not taking ABC (64) 
However, a study of 13 biomarkers in virologically suppressed patients taking ABC/3TC vs 
TDF/FTC found no significant change in either group after 48 weeks (65). The results of the 
DAD study (62) could have been confounded by te so-called allocation biases such as high 
cardiovascular risk and renal function. In the Veterans Affairs Study a weak correlation 
between ABC use and MI was found, disappearing entirely after statistical adjustment for 
renal disease (66).  
In November 2008, DHHS guidelines reclassified abacavir from a preferred first-line agent 
to an alternate agent, partly because of these data on cardiovascular risk.  
In the DAD study correcting the increased relative risk for antiretroviral-associated CVD for 
lipds attenuated this CVD risk by around 10% (55). In the ACTG 5202 study (11,12) fasting 
lipids at week 48 had increased more in the ABC/3TC arm than in the TDF/FTC arm 
(respectively; total cholesterol 0,87 mmol/L versus 0,67 mmol/L and triglycerides 0.28 
mmol/L versus 0.03 mmol/L) with no significant difference between groups in the change 
in the ratio of total cholesterol to HDL cholesterol. In a systemic review of  7 clinical trials 
with a total of 3,807 paticipants, studying initial treatment in naïve subjects receiving 
2NRTIs/efavirenz regimens the mean change in total cholesterol from baseline to 48 weeks 
was significantly greater in patients taking a non-TDF containing regimen (67).   
Bone mineral density loss associated with HIV infection and cART 
Many studies have documented an increased prevalence of osteopenia in HIV-infected 
individuals with dual x-ray absorptiometry bone densitometry (DEXA) scans. This finding 
is important since bone mineral density (BMD) predicts fracture risk (68). A higher fracture 
rate has been demonstrated among HIV-infected subjects compared with controls in a large 
healthcare system.(69). Many factors may play a role in the increased prevalence of 
osteopenia like vitamine D deficiency, low body mass, aging, corticosteroid use, alcoholism 
and HIV-infection. 
Decreased BMD has been found in both treatment-naive and treated HIV-infected patients. 
Ongoing BMD loss over time has been observed in some treatment studies, although it is 
uncertain whether it is due to drug toxicity since it is difficult to differentiate between effects 
associated with antiretrovirals and other factors. In addition the presence and strength of 
antiviral-related factors is difficult to ascertain as combinations of classes of antiretroviral 
drugs are used. 
In the GS 903 study comparing d4T/3TC and TDF/3TC, each combined with efavirenz in 
treatment-naive patients, after an an initial decrease in BMD was found in both study arms 
but stabilized after 24 weeks. By week 144, the mean decrease in BMD of the spine was 
significantly different 0.9% in the d4T/3TC arm and  2.2% in the TDF/3TC arm.  At baseline 
there was a relatively high incidence of both osteopenia and osteoporosis in both study 
arms, but there was no significant difference in rates of new-onset osteopenia or progression 
to osteoporosis through week 144 (70). 
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In the STEAL study, 360 virologically suppressed patients were randomized to switch their 
current NRTIs to either ABC/3TC or TDF/FTC. No significant change in spine or hip T 
scores were observed in the ABC/3TC arm, but BMD at spine and hip decreased in the 
TDF/FTC arm, and the difference between the regimens was statistically significant at 
weeks 48 and 96 (71). 
In a study comparing the effect of TDF versus ABC based regimens on BMD, BMD 
decreased early during therapy in both arms before stabilizing. The mean loss of BMD was 
statistically greater with TDF  and the loss correlated with biomarkers of bone turnover (72). 
Similar results were obtained in an other study comparing the safety aspects of ABC/3TC 
and TDF/FTC in 385 treatment-naive patients (73). 
In the ACTG 5202 metabolic substudy, there was an initial reduction in BMD in all stady 
arms, which stabilized after 48 weeks.  A significantly greater loss of BMD was seen at week 
96 with TDF/FTC versus ABC/3TC. This included a significant 2% greater reduction in 
lumbar spine BMD and a significant 1.5% greater reduction in hip BMD. No difference was 
found in fracture rates between study arms at week 48 (74). 
In the bone substudy of this trial, the initiation of antiretroviral therapy was associated with 
a decrease in bone mass of 2% to 4% that was independent of the regimen selected and 
stabilized by week 48; this decrease was greatest in patients who started a regimen that 
contained TDF (75). 
Thus overall, BMD appears to decline to some degree during the first several months after 
initiation of cART, regardless of regimen, but the decline may be slightly greater with TDF 
containing regimens. However, there are no conclusive data showing that therapy-
associated reductions in bone mineral density are also associated with an increased rate of 
fractures. 
3.2 Documentation 
The clinical documentation of the combinations is summarised in Table 2 
 
 Number of 
clinical trials* 
Years since 
registration 
Zidovudine/Lamivudine or 
emtricitabine 
 532/23 >10 
Emt: 8 
Didanosine/Lamivudine or 
emtricitabine 
165/10 >10 
Emt: 8 
Abacavir/Lamivudine or 
emtricitabine 
160/15 > 10 
Emt: 8 
Tenofovir/emtricitabine or 
Lamivudine 
78/115 
 
>10 
>10 
Table 2. Documentation 
* according  to the definition  of  National Institute of Health/PubMed (www.ncbi.nih.gov)    
4. Tolerability of anti-retroviral backbones 
4.1 Grade 1 and 2, mild to moderate side-effects 
The tolerability of a cART regimens is an important predictor of durability and long-term 
succes. Grade 1(mild adverse event) and grade 2 (moderate adverse event) (19)  may have a 
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significant influence on compliance and quality of life (22,26) and on the durability of a 
certain combination. It is not always evident which drug in a cART regimen is responsible 
for which side-effect. The HIV-infection as such or complications of opportunistic infections 
may lead to symptoms marked as adverse events of anti-retroviral medication.  
General symptoms as fatigue, pain, anorexia, sleep and concentration disturbances occur 
frequently (46). 
It  is difficult to give a reliable estimation of the relative incidence of different grade of adverse 
events, based on the EMEA and FDA data (76), because of the relative lack of randomised 
comparative studies with extended follow-up and asufficient number of participants.  
Cohort studies yield better insight as to why patients switch or stop certain antiretroviral 
drugs and how long they keep using the same regimen, in comparison with randomised 
studies which usually have a limited follow-up time.  
In the older cohort studies high rates of toxicity driven changes in antiretroviral drugs were 
common. For instance in the Swiss HIV Cohort Study, with 2,674 patients, 35% stopped 
treatment with at least one drug during the observation period of 3.2 years because of 
adverse events and/or intolerability and 41% stopped the combination of anti-retroviral 
drugs at least once or completely changed to another combination (77).   
In the Italian ICONA-cohort (78),  36% of the 862 patients stopped because of side-effects 
during study period of 45 weeks and only 5% because of virologic failure.  
Earlier initiation of cART, lower pill burden and dosing schemes of once or twice daily, 
together with declining toxicity, have improved tolerability.   
In the Athena-cohort the incidence per 100 patient years of toxicity driven changes of cART 
during the first 3 years after the start of therapy decreased from 29% in 1996 to 15% in 2008. 
Significant decline in  toxicity driven changes of cART started to be apparent after calendar 
year 2000. The incidence of toxicity driven changes of cART is highest in the first 3 month 
after initiation.  
5. Easy of use 
5.1 Ease of use (dosage frequency, number of tablets per day) 
The combinations of ABC/3TC, TDF/FTC and ddI/FTC or 3TC can be given once daily.  
ZVD/3TC (Combivir® )has to be given twice daily. The other combinations are given once 
or twice daily. The combinations of ABCbacavir/Lamivudine (Kivexa®, Epzicom®) and  
TDT/FTC (Truvada ®) can be given as one tablet per day. TDT/FTC in combination with 
efavirenz can be given in one tablet (Atripla ®) 
DdI is given  2 hours  before  or after food. The rest of the drugs can be taken irrespective of 
food.  
6. Applicability 
6.1 Availability of different formulations 
Liquid or dispersible formulations are available for ddI. 
6.2 Drug interactions 
Abacavir 
Abacavir is not significantly metabolised by CYP450, which makes serious reactions 
regarding inhibition or induction of CYP450 enzymes unlikely (80).  No interactions were 
seen with adefovir, amprenavir, indinavir, ZVD and 3TC (50). 
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Enzymeinducers like rifampicin, phenobarbital and phenytoin may decrease the plasma 
concentrations of abacavir to a minor extent through an effect on UDP-
glucuronyltransferases [72]. 
Alcohol may decrease the AUC of abacavir by 40% (81,82). 
Didanosine 
The AUC of ddI doubles during simultaneous use of ganciclovir. Didanosine has no 
significant effect on the pharmacokinetics of zidovudine (83). 
No clinically relevant interaction occurs between ddI with ritonavir, nevirapine, 
emtricitabine and nelfinavir (84). 
Ribavirine may increase intracellular levels of ddI.  The relevance of this is unknown. 
Didanosine decreases the bioavailability of ciprofloxacin during simultaneous intake. It is 
recommended to take ciprofloxacin an hour before or at least 4 hours after ddI (84). 
Didanosine showed no interaction with indinavir and fluconazole. Ketoconazole and 
itraconazole increase the AUC of ddI, maar these interactions do not  appear te be very 
relevant.  
The AUC of ddI increases by 50% in combination with tenofovir often leading to ddI 
toxicity (3). 
Xanthine oxidase plays a role in the metabolism of didanosine, interactions with inhibitors 
of xanthine oxidase, like allopurinol, may theoretically decrease the clearance of didanosine. 
Emtricitabine 
Tenofovir and FTC do not affect each other’s pharmacokinetics (85, 86). Emtricitabine is 
metabolised to a limited extent and is excreted unchanged in the urine through glomerular 
filtration and active tubular secretion(85).  Interactions regarding to inhibition of active 
tubular secretion cannot be excluded, maar have not been studied (85).  
Emcitabrine shows no pharmacokinetic interactions with protease inhibitors or with ddI (85).   
Lamivudine 
Lamivudine shows few metabolic interactions. The drug is excreted in an unchanged form 
through glomerular filtration and active tubular secretion (87, 88).  
No interaction is seen with ZVD and ddI (87, 88).  
Trimethoprim may decrease active tubular secretion, increasing the AUC of lamivudine 
by 40% (87, 88). Applications of high dose co-trimoxazole in pneumocystis carinii 
infections should not be combined with lamivudine (87). There is inadequate 
documentation on a possible interaction with intravenous ganciclovir or foscarnet. This 
combination should be avoided. 
Tenofovir 
Tenofovir is mainly excreted uchanged in the urine through glomerular filtration and active 
tubular secretion (90,91).  Interactions regarding to inhibition of active tubular secretion 
cannot be excluded, but have not been studied (90). 
Tenofovir and FTC have no effect on each other’s pharmacokinetics (85, 86,91). 
The AUC of  TDF increases by 30% in combination with lopinavir and ritonavir or atazanavir 
(92,93). Tenofovir may decrease the AUC of atazanavir by 25%. The AUC of lopinavir 
increases by 15% by tenofovir. Tenofovir shows no interaction with saquinavir (91).  
The AUC of ddI increases by 50% in combination with tenofovir (91). This may increase the 
risk of pancreatitis and other ddI related toxicity. The AUC of atazanavir decreases by 25% 
in combination with TDF (86). 
Tenofovir showed no interactions with indinavir, methadon, ribavirine or rifampicin (91,93, 94).  
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Zidovudine 
Zidovudine is mainly glucuronidated. The drug may theoretically show interactions with a 
large number of drugs which are also excreted through glucuronidation, like aspirin,  
NSAIDs, penicillins and oxazepam. Very limited data on the relevance of these possible 
interactions is available (95).  
The bioavailability of zidovudine may be decreased to a limited extent (22%) by 
simultaneouse intake with food (96). 
The renal clearance of zidovudine decreases by 50% during simultaneous use of co-
trimoxazole (96). This interaction is only relevant in disturbed glucuronidation of zidovudine.  
Rifampicin lowers the AUC of zidovudine by 50%,  an interaction with rifabutin is not very 
relevant, a 14% decrease of the AUC of zidovudine was seen (96). 
The AUC of ZVD increases by 75% in combination with fluconazole (96).  
Zidovudine may cause an unpredictable interaction with phenytoin (increase of decrease of 
the phenytoin levels). Phenytoin levels have to be checked on a regular basis.  
Atovaquone increases the AUC of zidovudine by 35%.  Valproic acid and methadone may 
also lead to an increase in the AUC of zidovudine, but little data are available.  
Zidovudine is antagonistic in combination with ribavirine or stavudine.  
Nephrotoxic or myelosuppressive drugs may increase potential side-effects of ZVD (SPC on 
zidovudine).  
6.3 Approved indications 
There are no major differences in the approved indications. The applicability in children is 
described in 5.5. 
Treatment co-infections 
Lamivudine, emtricitabine and tenofovir also have anti hepatitis B virus activity. An 
advantage of these drugs is that  “two in one” treatment is possible  It is recommended that 
lamivudine or emtricitabine should be combined with tenofovir (97) in case of hepatitis B 
co-infection. Only lamivudine is approved for this indication. 
6.4 Contra-indications 
All drugs are contra-indicated in case of hypersensitivity. 
Hypersensitivity to abacavir may be very serious.  
6.5 Use in children and elderly 
No dose adjustments are necessary in the elderly. 
Zidovudine/lamivudine (Combivir) and abacavir/lamivudine (Kivexa) can be used in 
children from 12 years. The individual components can be used from 3 months. 
Lamivudine can be used from 3 months 
Didanosine tablets can be used from 6 years. 
Tenofovir and emcitabine are only applicable in adults. 
6.6 Use in renal and hepatic disease 
A dose reduction is necessary in case of renal function impaiment. Abacavir/Lamivudine 
should not be used when the creatinine clearance is lower than 50 ml/min. 
Tenofovir/Emtricitabine should bot be used when the creatinine clearance is lower than 
30 ml/min. 
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No dose adjustments are usually necessary in patients with liver disease.  
6.7 Use in pregancy and lactation 
A variable extent of mitochondrial damage may occur during in utero exposition to 
nucleoside-analogues. This may  lead to hematologic toxicity or metabolic disturbances.  
All drugs should be avoided during lactation. None of the combinations is recommended in 
case of pregnancy, but they are usually not absolutely contra-indicated.  
6.8 Special precautions 
 
Zidovudine/Lamivudine 
(Combivir) 
Monitoring of hematologic parameters (ZVD)
Lowering of the dosage of ZVD in abnormal hematologic 
parameters  
Therapy cessation during signs of pancreatitis (ZVD and 3TC) 
Lactic acidosis has been described. Therapy should be stopped 
in case of hyperlactatemia or metabolic acidosis 
Use with great caution in case of hepatomegaly, hepatitis or risk 
factors for  liverdiseases (3TC) 
Cessation of L may lead to increased symptoms in patients who 
also have hepatitis B.
Didanosine/Lamivudine Great caution with pancreatitis in the anamnesis (ddI and 3TC) 
Peripheral neuropathy may occur (ddI) 
Changes in the retina and N.opticus are to be checked in 
children (ddI) 
Use with great caution in case of hepatomegaly, hepatitis or 
riskfactors for  liverdiseases (3TC) 
Lactic acidosis has been described. Therapy should be stopped 
in case of hyperlactatemia or metabolic acidosis (ddI and 3TC)  
Patients with hepatitis B or C have an increased risk on serious 
hepatic side-effects (ddI) 
Lipodystrophy may occur (ddI) 
Cessation of L may lead to increased symptoms in patients who 
also have hepatitis B.
Abacavir/Lamivudine 
(Kivexa) 
Cessation of therapy during signs of pancreatitis (ABC and 3TC) 
Lactic acidosis has been described. Therapy should be stopped 
in case of hyperlactatemia or metabolic acidosis 
Use with great caution in case of hepatomegaly, hepatitis or risk 
factors for  liverdiseases (3TC) 
Lipodystrophy may occur (3TC) 
Patients with hepatitis B or C have an increased risk on serious 
hepatic side-effects  
Cessation of 3TC may lead to increased symptoms in patients 
who also have hepatitis B.
Tenofovir/Lamivudine Tenofovir may lower the BMD (TDF)
No not use in case of the HIV-1 K65R mutation (TDF) 
Lactic acidosis has been described. Therapy should be stopped 
in case of hyperlactatemia or metabolic acidosis (TDF) 
Cessation of L may lead to increased symptoms in patients who 
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also have hepatitis B.
Use with great caution in case of hepatomegaly, hepatitis or risk 
factors for  liverdiseases (3TC) 
Renal function should be checked. Combination with 
nephrotoxic  drugs is not recommended (3TC)
Tenofovir/Emtricitabine 
(Truvada) 
Do not combine with lamivudine 
Combination with a  third nucleoside analogue is not 
recommended  beause of  possible virologic failure. 
The tablet contains lactose. 
Renal function should be checked. Combination with 
nephrotoxisc  drugs is not recommended (TDF) 
No not use in case of the HIV-1 K65R mutation (TDF) 
Tenofovir may lower the bone mineral density (TDF) 
Patients with hepatitis B or C have an increased risk on serious 
hepatic side-effects (TDF) 
Cessation of TDF/FTC may lead to increased symptoms in 
patients who also have hepatitis B.
Didanosine/Emtricitabine Great caution with pancreatitis in the anamnesis (ddI) 
Peripheral neuropathy may occur (ddI) 
Changes in the retina and N.opticus are to be checked in 
children (ddI) 
Lactic acidosis has been described. Therapy should be stopped 
in case of hyperlactatemia or metabolic acidosis (ddI) 
Lipodystrophy may occur (ddI) 
Patients with hepatitis B of C have an increased risk on serious 
hepatic side-effects (ddI) 
Lipodystrophy may occur (ddI)
7. Acquisition cost 
Acquisition cost excluded for VAT  in Euro (“vergoedingsprijs”, Z-Index July 2011) 
 
  Cost per month in 
Euro 
Zidovudine/Lamivudine 
(Combivir) 
2 dd 300/150 mg  379 
Didanosine ER (Videx) 
Lamivudine (Epivir) 
1 dd 400 or 250 mg (weight based) 
300 mg in 1-2 doses 
306/336 
Abacavir/Lamivudine 
(Kivexa, Epzicom) 
1 dd 600/300 mg  422 
Tenofovir (Viread) 
Lamivudine (Epivir) 
1 dd 245 mg 
300 mg in 1-2 doses 
510 
Tenofovir/Emtricitabine 
(Truvada) 
1 dd 200/245 mg 510 
Didanosine ER (Videx) 
Emtricitabine (Emtriva) 
1 dd 400 or 250 mg (weight based) 
 200 mg 1 dose 
 
313/343 
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8. Conclusion 
Optimal care requires individualized management and ongoing attention to relevant 
scientific and clinical information.  The availability of new antiretroviral drugs since the 
introduction of the fist cART has expanded treatment choices. Guidelines are presented as 
recommendations if the supporting evidence warrants routine use in a particular situation 
and as considerations if data are preliminary or incomplete but suggestive. But the 
importance of adherence, emerging long-term complications of therapy, recognition and 
management of antiretroviral failure is often underestimated and there is but to often little 
data to guide our choices. 
The judgement of the relative efficacy and safety of the various NRTI backbones in the 
treament of HIV infection is hindered by the fact that there are only few direct comparative 
studies. This makes it difficult to make firm statements concerning the pros and cons of the 
individual drugs concerning efficacy and safety.  
In this InforMatrix manuscript, no firm conclusions are drawn by the authors. The purpose 
of this manuscript is to facilitate discussion on the properties of each treatment option for 
HIV by using only clinically relevant selection criteria by providing an up-to-date overview. 
The InforMatrix program will be made available in an interactive format on 
www.informatrix.nl. By means of the program, the user can assign a relative weight to each 
main selection criterion (with a total of 30 points to be distributed) and can judge the 
properties of each therapeutic option per criterion on the basis of his own personal expertise 
and/or the present document. Zero to ten points can be assigned to each treatment option 
on each criterion. The program is freely accessible. 
The present InforMatrix manuscript is specific for the Netherlands, because the Dutch 
available formulations and Dutch prices were used. The most important part of the paper 
(efficacy, safety and tolerability) is internationally valid. Local adjustments are necessary for 
an optimal use of the method in other countries. This could also include price-adjustments 
for the individual hospitals in other countries. 
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